Eribulin Provides a Remarkable Effect in Trabectedin-Resistant Myxoid Liposarcoma

Adriamycin-based chemotherapy is commonly used for malignant soft tissue sarcoma including myxoid liposarcoma. However, in the case of unavailability or failure of the adriamycin-based regimen, trabectedin or eribulin can produce a good antitumor effect for myxoid liposarcoma. We relate the experien...

Full description

Saved in:
Bibliographic Details
Published in:Case reports in orthopedics 2020-01, Vol.2020 (2020), p.1-7
Main Authors: Wakamatsu, Toru, Imura, Yoshinori, Yamashita, Katsunari, Sabe, Hideaki, Tamiya, Hironari, Takenaka, Satoshi
Format: Article
Language:English
Subjects:
Biopsy
Breast cancer
Cancer therapies
Case Report
Case reports
Chemotherapy
Drug dosages
Liposarcoma
Medical prognosis
Metastasis
Patients
Radiation therapy
Sarcoma
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Adriamycin-based chemotherapy is commonly used for malignant soft tissue sarcoma including myxoid liposarcoma. However, in the case of unavailability or failure of the adriamycin-based regimen, trabectedin or eribulin can produce a good antitumor effect for myxoid liposarcoma. We relate the experience of a 64-year-old female with myxoid liposarcoma, who noticed a nodule on her left thigh and visited our institute. At initial presentation, the tumor was 18.7 cm in diameter, and the magnetic resonance imaging (MRI) showed a malignant lipomatous tumor with a myxoid component. We recommended that she undergo treatment; however, she refused. Three years later, the tumor had grown larger, so she finally decided to undergo treatment. A needle biopsy revealed a myxoid liposarcoma. The tumor massively involved the neurovascular structures; we thus determined that hip disarticulation was inevitable. Two years later, metastases in the right thigh, left lung, right ileum, and abdominal space were pointed out and chemotherapy was initiated. Adriamycin was unusable due to cardiac dysfunction, so trabectedin was administered; however, the tumors progressed. Eribulin was subsequently started and has been considerably effective for more than 2 years without severe adverse effects. In conclusion, we experienced a case showing the remarkable and long-lasting effect of eribulin against trabectedin-resistant myxoid liposarcoma.
ISSN:2090-6749
2090-6757
DOI:10.1155/2020/8873185